pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›FENOFIBRATE
drug
save

FENOFIBRATE

Marketedupdated 3mo ago
by Orit Laboratories LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval54 co-mentions · 27 sources
  • drugANTARA (MICRONIZED)47 co-mentions · 29 sources
  • drugAntara47 co-mentions · 29 sources
  • drugFenoglide29 co-mentions · 29 sources
  • tagSmall Molecule27 co-mentions · 27 sources
  • drugFENOFIBRIC ACID16 co-mentions · 8 sources
  • drugcholine fenofibrate DR16 co-mentions · 8 sources
  • drugcholine fenofibrate8 co-mentions · 8 sources

indications

investigational
Hyperlipidemia

all catalysts(19)

approval · 19
Nov 30, 2004
approval
22y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Oct 21, 2005
approval
21y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Jun 3, 2008
approval
18y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Mar 1, 2012
approval
14y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Dec 19, 2012
approval
14y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Oct 18, 2013
approval
13y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Sep 4, 2014
approval
12y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Aug 31, 2015
approval
11y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Nov 9, 2016
approval
10y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Nov 29, 2016
approval
10y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Sep 11, 2017
approval
9y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
May 18, 2018
approval
8y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Nov 7, 2018
approval
8y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Feb 4, 2019
approval
8y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
May 15, 2019
approval
7y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Jun 3, 2021
approval
5y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Jul 30, 2024
approval
2y ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Oct 1, 2025
approval
11mo ago
ANTARA (MICRONIZED) (FENOFIBRATE) — FDA approval
FENOFIBRATE
→
Jan 21, 2026
approval
7mo ago
FENOFIBRATE — FDA approval
FENOFIBRATE
→
view all 19 catalysts →

Trials studying FENOFIBRATE

  • phase3The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.active not recruitingn=412
  • phase3Fenofibrate for Prevention of DR Worseningrecruitingn=560
  • —Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russiarecruitingn=2,382
  • phase3A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-Ccompletedn=353
  • phase3Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)completedn=576
  • phase3Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)completedn=587
  • phase4Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemiarecruitingn=56

Patent cliff

source: FDA Orange Book
first barrier falls
May 31, 2033
~6.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (1)

  • May 31, 2033formulationUS 9314447

News(0)

no news has mentioned this drug yet

brand
FENOFIBRATE
generic
FENOFIBRATE
indication
Hypercholesterolemia
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?